Business
Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum
Radioligand Therapeutics in Cancer Treatment Market Radioligand Therapeutics in Cancer Treatment Market Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapeutics in Cancer Treatment: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for radioligand therapeutics in cancer treatment is poised for significant expansion, estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030, at a CAGR of 13.1%. Radioligand therapy (RLT), leveraging targ
About this update from Novartis Ag
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Radioligand Therapeutics in Cancer Treatment Market","length":51,"tagName":"p"},{"type":"image","alt":"Radioligand Therapeutics in Cancer Treatment Market","displaySize":"","headline":null,"caption":"Radioligand Therapeutics in Cancer Treatment Market","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globenewswire.com/cc7f3591355825461eaf978148243f74"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tWsBMXJBBbG9T7rmorWcSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc7f3591355825461eaf978148243f74","width":600,"height":400}}},{"type":"text","content":"Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapeutics in Cancer Treatment: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for radioligand therapeutics in cancer treatment is poised for significant expansion, estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030, at a CAGR of 13.1%.","length":370,"tagName":"p"},{"type":"text","content":"Radioligand therapy (RLT), leveraging targeted ligands to deliver therapeutic radionuclides to cancer cells, is validated for treating advanced prostate cancer and neuroendocrine tumors. Novartis AG's Pluvicto (Lu-177 PSMA) and Lutathera (Lu-177 SSTR) have catalyzed commercial momentum, underpinning the approved market. RLT's benefits in selected patients are complemented by specialized infrastructure and focused management of treatment-related effects and radiation safety.","length":486,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globene...